Previous 10 | Next 10 |
Socket Mobile (NASDAQ: SCKT ) +142% on launching 2 barcode scanners. More news on: Socket Mobile, Inc., Wilhelmina International, Inc., TCR2 Therapeutics Inc., Stocks on the move, , Read more ...
TCR2 Therapeutics (NASDAQ: TCRR ) announces positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 trial for mesothelin-expressing solid tumors. More news on: TCR2 Therapeutics Inc., Healthcare stocks news, Read more ... ...
- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients - Two RECIST unconfirmed partial responses and two patients with stable disease through six months - Manageable toxicity profile, with only one patient exhibiting TC-210-...
TCR 2 Therapeutics (NASDAQ: TCRR ) up 7.6% AH, in reaction to company's plans to discuss initial data from the Phase 1 portion of Phase 1/2 trial of its lead drug TC-210, in patients with mesothelin-expressing solid tumors, on Monday. More news on: TCR2 Therape...
CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company plans to discuss initial data from the Pha...
CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2...
CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced an expansion of its leadership team to strengthen e...
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will present an e-poster at the American As...
TCR2 Therapeutics (NASDAQ: TCRR ): Q1 GAAP EPS of -$0.65 beats by $0.76 . More news on: TCR2 Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Continued progress on treatment of TC-210 patients with interim update from Phase 1 portion of Phase 1/2 clinical trial anticipated in mid-2020 Continued progress of TC-110 with initiation of leading clinical sites participating in Phase 1/2 clinical trial that include Sarah Cannon Resea...
News, Short Squeeze, Breakout and More Instantly...
TCR2 Therapeutics Inc. Company Name:
TCRR Stock Symbol:
NYSE Market:
TCR2 Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (TCR 2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for...
NEW YORK, NY / ACCESSWIRE / April 13, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Univar Solutions Inc. (NYSE:UNVR)'s ...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Global Infrastructure, Inc....